89 reports

  • 5.6 LUCENTIS (RANIBIZUMAB)

Immunotoxicity of monoclonal antibodies. mAbs; ##(##): ##-## Duan C, et al. (2015).

  • Medical Biotechnology
  • Monoclonal Antibody
  • AbbVie Inc.
  • Johnson & Johnson
  • Novartis AG
  • OVERVIEW OF RECENT KEY EVENTS IN AD
  • OF CONTENTS

" I' m intrigued by the anti-tau monoclonal antibodies.

  • Dementia
  • Monoclonal Antibody
  • United States
  • Forecast
  • Novartis AG
  • ORPHAN AND RARE DERMATOLOGY DRUGS MARKET, GLOBAL, ANNUAL REVENUE FORECAST FOR KEY PRODUCTS ($M), 2017-2024

For example, anti-fibrillin-## antibodies can activate fibroblasts, and antibodies to matrix metalloproteinase-## (MMP-##) and MMP-## can prevent the breakdown of excessive collagen.

  • Autoimmune Disease
  • Dermatological Condition
  • Dermatological Treatment
  • Monoclonal Antibody
  • Novartis AG
  • 7.3 PRODUCT PROFILES - MONOCLONAL ANTIBODY INJECTABLE THERAPIES
  • LEADING DISEASE-MODIFYING DRUGS FOR THE TREATMENT OF MS, 2017

RANDOMIZED PHASE I TRIALS OF THE SAFETY/ TOLERABILITY OF ANTI-LINGO-## MONOCLONAL ANTIBODY BIIB##.

  • Monoclonal Antibody
  • Therapy
  • United States
  • Forecast
  • Novartis AG

Alzumab is an anti-CD## monoclonal antibody.

  • Autoimmune Disease
  • Monoclonal Antibody
  • Therapy
  • AbbVie Inc.
  • Novartis AG
  • tremelimumab
  • for oncology

Distinct PD-L## binding characteristics of therapeutic monoclonal antibody durvalumab.

  • Breast Cancer
  • Monoclonal Antibody
  • Targeted Therapy
  • Therapy
  • Novartis AG

THESE TWO THERAPIES ARE MONOCLONAL ANTIBODY (MAB) PRODUCTS THAT TARGET INTERLEUKIN RECEPTORS, AND TYPIFY THE GROWING PROMINENCE OF MABS IN THE TREATMENT OF RESPIRATORY DISEASES.

  • Monoclonal Antibody
  • Pharmaceutical
  • Respiratory Disease
  • Therapy
  • Novartis AG
  • Market drivers

This should lead to the development of novel diagnostic tools and products such as monoclonal antibodies.

  • Monoclonal Antibody
  • Neurological Disorder
  • Alexion Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG

Monoclonal antibodies (mAbs) are the newest class of drugs, predominately used in the treatment of psoriasis.

  • Dermatological Condition
  • Dermatology
  • Monoclonal Antibody
  • Therapy
  • Novartis AG

TWO MONOCLONAL ANTIBODY (MAB) THERAPIES ARE UNDERGOING CLINICAL TRIALS, ONE OF WHICH IS IN PHASE III.

  • Biosimilar
  • Medical Biotechnology
  • Monoclonal Antibody
  • Therapy
  • Novartis AG

UNLIKE THE GENERICS OF SMALL MOLECULES, WHICH ARE OFTEN PRICED AT A SUBSTANTIAL DISCOUNT TO THE ORIGINATOR BRAND, BIOSIMILARS OF THE MONOCLONAL ANTIBODY (MAB) THERAPIES FOR PLAQUE PSORIASIS ARE PRICED ONLY MARGINALLY LOWER THAN THE CORRESPONDING BIOLOGIC BRAND.

  • Dermatological Condition
  • Monoclonal Antibody
  • Therapy
  • World
  • Novartis AG
  • Anti-CD20 Monoclonal Antibody

CANADIAN KEY OPINION LEADER MOST OF THE CURRENT PHASE III REGISTRATIONAL TRIALS THAT ARE INVESTIGATING COMBINATION THERAPIES INVOLVE AT LEAST ONE ANTI-CD## MONOCLONAL ANTIBODY.

  • Immunotherapy
  • Monoclonal Antibody
  • Therapy
  • Market Size
  • Novartis AG

CD##+ T cells secrete cytokines that increase antibody production by B cells.

  • Clinical Trial
  • Hepatitis
  • Monoclonal Antibody
  • Therapy
  • Novartis AG
  • V. Advanced/Stage IV/Metastatic RCC

Twelve are monoclonal antibody including two antibody-drug conjugates.

  • Cancer
  • Monoclonal Antibody
  • Renal Cancer
  • Therapy
  • Novartis AG

Monoclonal antibodies had one deal with an undisclosed deal value.

  • Monoclonal Antibody
  • Pharmaceutical
  • Therapy
  • Clearside Biomedical, Inc.
  • Novartis AG

It may not be absolutely high efficacy like the monoclonal antibodies.

  • Monoclonal Antibody
  • United States
  • Forecast
  • Market Competition
  • Novartis AG
  • NOVARTIS - GP2013 (RITUXIMAB)
  • NOVARTIS - CP2013 (RITUXIMAB)

FIGURE ##-##: MONOCLONAL ANTIBODIES IN CANCER TREATMENT, OPDIVO PERFORMANCE VS.

  • Lymphoma
  • Monoclonal Antibody
  • Targeted Therapy
  • Therapy
  • Novartis AG
  • Pipeline Analysis

Monoclonal antibodies have a strong presence in the Preclinical, Phase I, Phase II and Phase III stages of development.

  • Monoclonal Antibody
  • Therapy
  • Market Size
  • AstraZeneca PLC
  • Novartis AG
  • CLINICAL TRIALS - LEADING INDUSTRY SPONSORS
  • TOP INDUSTRY SPONSORS OF CLINICAL TRIALS IN AXSPA

WITH MOST OF THE PHASE I DRUGS BEING MONOCLONAL ANTIBODIES, THIS STILL REMAINS THE MOLECULE TYPE OF CHOICE FOR FUTURE DRUG DEVELOPMENT. ## Source: GlobalData, Pharma Intelligence Center [Accessed May 2018] ## ## ## ## ## ## ## ## ## ## ## ## Fusion Protein

  • Clinical Trial
  • Monoclonal Antibody
  • AbbVie Inc.
  • Eli Lilly & Co.
  • Novartis AG

TREGALIZUMAB IS ANOTHER HIGH-RISK PHASE II INVESTIGATIONAL DRUG, AN ANTI-CD## MONOCLONAL ANTIBODY, INDUCING SELECTIVE ACTIVATION OF REGULATORY T-CELLS.

  • Autoimmune Disease
  • Dermatological Condition
  • Dermatology
  • Monoclonal Antibody
  • Novartis AG

Herceptin is a monoclonal antibody targeting the HER## receptor.

  • Monoclonal Antibody
  • United States
  • Company
  • Forecast
  • Novartis AG
  • 7.1.3 DEALS BY MOLECULE TYPE, MECHANISM OF ACTION AND VALUE

This segment consists largely of premium systemic monoclonal antibodies (mAb), which are highly commercially successful due to their widespread use and high cost.

  • Autoimmune Disease
  • Immunology
  • Monoclonal Antibody
  • Therapy
  • Novartis AG
  • NEURODEGENERATIVE DISORDERS, GLOBAL, ANNUAL REVENUE FOR KEY PRODUCTS ($BN), 2015-2022

Tysabri is a recombinant humanized immunoglobulin (IgG##) monoclonal antibody (mAb).

  • Clinical Trial
  • Dementia
  • Monoclonal Antibody
  • Therapy
  • Novartis AG

Herceptin is the gold standard monoclonal antibody (mAb) for the treatment of HER##positive disease, and is prescribed in nearly all settings.

  • Breast Cancer
  • Monoclonal Antibody
  • Targeted Therapy
  • Therapy
  • Novartis AG

Avastin is a recombinant, humanized, monoclonal immunoglobulin (IgG) ## antibody developed by Roche.

  • Lung Cancer
  • Monoclonal Antibody
  • Targeted Therapy
  • Therapy
  • Novartis AG

Human anti-PD-L## monoclonal antibody, Immune checkpoint inhibitor, Oncolytic.

  • Cancer
  • Monoclonal Antibody
  • Oncology
  • Therapy
  • Novartis AG

MediGene AG BioInvent International AB Genmab A/ S Ablynx NV Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical mAb mAb mAb mAb mAb mAb mAb Hormonal signaling Undisclosed Undisclosed Undisclosed Undisclosed Undisclosed Undisclosed Monoclonal

  • Immunotherapy
  • Monoclonal Antibody
  • Oncology
  • Therapy
  • Novartis AG
  • Pipeline Analysis

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.

  • Asthma
  • Clinical Trial
  • Monoclonal Antibody
  • Therapy
  • Novartis AG
  • 4.2.1 NAKED MONOCLONAL ANTIBODIES
  • 4.2 MONOCLONAL ANTIBODIES

MONOCLONAL ANTIBODIES ARE MAINLY OF THREE TYPES SUCH AS NAKED MONOCLONAL ANTIBODIES, BISPECIFIC MONOCLONAL ANTIBODIES AND CONJUGATED MONOCLONAL ANTIBODIES.

  • Immunotherapy
  • Monoclonal Antibody
  • Therapy
  • AbbVie Inc.
  • Novartis AG
  • 6.4 BONE METASTASES
  • 6.3.2 MUCOSTA (OFF-LABEL) AND GELS FOR ORAL MUCOSITIS

Xilonix (MABp##) is a first-in-class human immunoglobulin G## (IgG##) monoclonal antibody being developed by XBiotech to treat the debilitating symptoms of colorectal cancer, including cachexia.

  • Cancer
  • Chemotherapy
  • Monoclonal Antibody
  • Therapy
  • Novartis AG